Kronos Bio Statistics
Total Valuation
Kronos Bio has a market cap or net worth of $53.73 million. The enterprise value is -$22.52 million.
| Market Cap | 53.73M |
| Enterprise Value | -22.52M |
Important Dates
The next estimated earnings date is Thursday, August 7, 2025, after market close.
| Earnings Date | Aug 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Kronos Bio has 61.05 million shares outstanding. The number of shares has increased by 3.52% in one year.
| Current Share Class | 61.05M |
| Shares Outstanding | 61.05M |
| Shares Change (YoY) | +3.52% |
| Shares Change (QoQ) | +0.77% |
| Owned by Insiders (%) | 3.40% |
| Owned by Institutions (%) | 27.13% |
| Float | 58.98M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 5.78 |
| Forward PS | n/a |
| PB Ratio | 0.67 |
| P/TBV Ratio | 0.67 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 12.93, with a Debt / Equity ratio of 0.30.
| Current Ratio | 12.93 |
| Quick Ratio | 12.66 |
| Debt / Equity | 0.30 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -59.49% and return on invested capital (ROIC) is -23.57%.
| Return on Equity (ROE) | -59.49% |
| Return on Assets (ROA) | -21.73% |
| Return on Invested Capital (ROIC) | -23.57% |
| Return on Capital Employed (ROCE) | -50.47% |
| Revenue Per Employee | $919,200 |
| Profits Per Employee | -$6.45M |
| Employee Count | 10 |
| Asset Turnover | 0.06 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -12.87% in the last 52 weeks. The beta is 1.64, so Kronos Bio's price volatility has been higher than the market average.
| Beta (5Y) | 1.64 |
| 52-Week Price Change | -12.87% |
| 50-Day Moving Average | 0.79 |
| 200-Day Moving Average | 0.91 |
| Relative Strength Index (RSI) | 65.76 |
| Average Volume (20 Days) | 1,367,356 |
Short Selling Information
The latest short interest is 754,265, so 1.24% of the outstanding shares have been sold short.
| Short Interest | 754,265 |
| Short Previous Month | 547,885 |
| Short % of Shares Out | 1.24% |
| Short % of Float | 1.28% |
| Short Ratio (days to cover) | 0.60 |
Income Statement
In the last 12 months, Kronos Bio had revenue of $9.19 million and -$64.49 million in losses. Loss per share was -$1.07.
| Revenue | 9.19M |
| Gross Profit | 9.19M |
| Operating Income | -50.60M |
| Pretax Income | -102.85M |
| Net Income | -64.49M |
| EBITDA | -49.14M |
| EBIT | -50.60M |
| Loss Per Share | -$1.07 |
Balance Sheet
The company has $99.73 million in cash and $24.09 million in debt, giving a net cash position of $75.65 million or $1.24 per share.
| Cash & Cash Equivalents | 99.73M |
| Total Debt | 24.09M |
| Net Cash | 75.65M |
| Net Cash Per Share | $1.24 |
| Equity (Book Value) | 79.81M |
| Book Value Per Share | 1.31 |
| Working Capital | 93.99M |
Cash Flow
In the last 12 months, operating cash flow was -$54.38 million and capital expenditures $3,000, giving a free cash flow of -$54.38 million.
| Operating Cash Flow | -54.38M |
| Capital Expenditures | 3,000 |
| Free Cash Flow | -54.38M |
| FCF Per Share | -$0.89 |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -550.46% |
| Pretax Margin | -701.53% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Kronos Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.52% |
| Shareholder Yield | -3.52% |
| Earnings Yield | -121.39% |
| FCF Yield | -102.36% |
Analyst Forecast
The average price target for Kronos Bio is $1.63, which is 85.23% higher than the current price. The consensus rating is "Buy".
| Price Target | $1.63 |
| Price Target Difference | 85.23% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | 48.62% |
| EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Kronos Bio has an Altman Z-Score of -6.94 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -6.94 |
| Piotroski F-Score | 3 |